iPSC-based Diabetes Modeling

iPSC technologies provide valuable tools for establishing new in vitro disease models. Creative Bioarray is committed to using patient cells for disease modeling to help clients better understand the pathogenesis of various forms of diabetes. Our professional solutions will accelerate the development of drug screening and treatment in the field of diabetes.

iPSC for Modeling Diabetes

Diabetes is a complex group of metabolic disorders, with T1D and T2D being the most common forms of diabetes. The pathophysiology of these diseases is complex and influenced by multiple factors, including epigenetics, lifestyle and environment. Multiple rodent models of diabetes already exist, however, physiological differences between rodents and human islets have hindered a deeper understanding of these diseases. Therefore, researchers have used stem cell technology to create iPSCs from human patients to model diabetes and better understand the molecular mechanisms underlying the pathophysiology of diabetic disorders.

Disease modeling based on iPSC technology has received a lot of attention from researchers because iPSCs contain genetic information about the patients who generated them, and thus the disease-affected cell types differentiated from patient-derived iPSCs have the potential to recapitulate the disease phenotype in vitro. Recently, several reports have described the generation of iPSCs derived from patients with diabetes, including T1D and T2D, mitochondrial diabetes, and mature-onset diabetes of the younger types 1, 2, 3, 5 and 8, where a single gene mutation causes diabetes.

Fig 1. Disease modeling using patient-derived iPSCs.Fig.1 Disease modeling using patient-derived iPSCs. (Kondo, 2018)

Our Solutions

To help our clients analyze disease mechanisms in multiple forms of diabetes and develop new therapeutic agents using iPSC disease models, researchers at Creative Bioarray have made significant efforts to use patient cells for disease modeling to elucidate key features of human pancreatic development and diabetes disease progression.

  • We offer systemic solutions for disease modeling using patient-derived iPSCs in patients with diabetes-related diseases, including T1D, T2D, maturity-onset diabetes of the young (MODY), cystic fibrosis-related diabetes (CFRD), Wolfram syndrome (WS), monogenetic diabetes (MD), and neonatal diabetes (NeoD).
  • We provide solutions for our clients to gain insight into the disease mechanisms of diabetes. We combine disease modeling with gene editing and next-generation sequencing to help our clients uncover the impact of diabetes-causing mutations and diabetic phenotypes on multiple islet cell types.


  • Research on molecular mechanisms responsible for pathophysiology of diabetes
  • Drug screening
  • Development of patient-specific targeted therapies


  • Experienced researchers
  • Efficient technical support and trustworthy results
  • Customized solutions
  • High-cost performance

Creative Bioarray is a biotechnology company experienced in developing services related to the field of cell reprogramming. We have made great strides in using patient cells for disease modeling in many types of diabetes. With our professionalism and dedication, we offer our customers comprehensive, high-quality and affordable services. Please contact us for more details.


  1. Kondo, Y.; et al. iPSC technology-based regenerative therapy for diabetes. Journal of diabetes investigation. 2018, 9(2): 234-243.
For Research Use Only. Not For Clinical Use.